Open-label Adalimumab

BIOLOGICAL2 trials

Sponsors

Abbott, AbbVie (prior sponsor, Abbott)

Conditions

Axial SpondyloarthritisRheumatoid Arthritis

Phase 3

A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis

CompletedNCT00870467

AbbottRheumatoid Arthritis

Start: 2009-03-31End: 2011-08-31Updated: 2012-08-07

Study of Adalimumab in Patients With Axial Spondyloarthritis

CompletedNCT00939003

AbbVie (prior sponsor, Abbott)Axial Spondyloarthritis

Start: 2009-07-31End: 2013-08-31Updated: 2014-09-09

Related Papers

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.

2018-03-2729 citations

Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time.

2017-07-0122 citations

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases2016-06-24107 citations

Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial

Lara D. Veeken2014-01-1727 citations